PepGen Inc. Q1 2025 10-Q Summary
Business Context and Reporting Period
PepGen Inc. is a clinical-stage biotechnology company developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases, specifically Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). The company operates as an emerging growth company and smaller reporting company. This report covers the quarterly period ended March 31, 2025.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(30.2) million | $(18.0) million |
| Operating Expenses | $31.3 million | $19.8 million |
| Research & Development (R&D) | $25.4 million | $14.7 million |
| General & Administrative (G&A) | $5.9 million | $5.1 million |
| Cash, Cash Equivalents, and Marketable Securities | $97.8 million | $135.4 million (Total cash at end of period) |
| Net Cash Used in Operating Activities | $(22.9) million | $(22.5) million |
| Accumulated Deficit | $(301.7) million | $(199.5) million |
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss increased by $12.2 million (68%) compared to Q1 2024, driven primarily by a $10.6 million increase in R&D expenses.
- R&D Expense Drivers: The increase in R&D was attributable to a $7.8 million rise in manufacturing costs due to campaign timing, a $2.6 million increase in personnel-related costs (including $0.9 million in stock-based compensation), and a $1.2 million increase in clinical trial costs for lead programs.
- Liquidity Position: Total cash, cash equivalents, and marketable securities decreased from approximately $135.4 million at the end of Q1 2024 to $97.8 million as of March 31, 2025. This reflects ongoing operational burn and no financing activities in the current quarter.
- Stock-Based Compensation: Total stock-based compensation expense increased to $3.4 million in Q1 2025 from $2.0 million in Q1 2024.
Guidance, Outlook, and Risks
- Clinical Trial Status:
- PGN-EDO51 (DMD): The CONNECT1 Phase 2 study in Canada is ongoing. Health Canada has requested additional safety information before allowing dose escalation or further enrollment. The CONNECT2 Phase 2 study in the U.S. is under an FDA clinical hold (issued Dec 2024), and the company voluntarily paused the U.K. portion of CONNECT2 in March 2025 pending review of CONNECT1 data.
- PGN-EDODM1 (DM1): The FREEDOM Phase 1 study reported favorable safety and robust splicing correction in initial cohorts. The FREEDOM2 Phase 2 study is dosing participants in Canada and the U.K.
- Liquidity Outlook: Management believes current cash resources ($97.8 million) are sufficient to fund operations for at least 12 months from the filing date. The company expects to incur significant losses for the foreseeable future and will need to raise substantial additional capital.
- Key Risks:
- Failure to resolve the FDA clinical hold on PGN-EDO51 or address Health Canada safety concerns.
- Need for additional financing; inability to raise capital could force delays or discontinuation of programs.
- Dependence on third-party manufacturers and CROs.
- Uncertainty regarding clinical trial outcomes and regulatory approval pathways.
Investor Verification Checklist
- Verify the status of the FDA clinical hold on the CONNECT2 trial and the timeline for resolution.
- Confirm the specific safety concerns raised by Health Canada regarding the CONNECT1 trial and the company's response plan.
- Monitor cash burn rate and the timeline for the next anticipated capital raise given the $97.8 million liquidity position.
- Review upcoming data readouts for the 10 mg/kg cohort in CONNECT1 (expected Q3 2025) and the 15 mg/kg cohort in FREEDOM (expected H2 2025).
- Assess the impact of increased manufacturing costs on future R&D budgeting.